Miami, FL-December 5, 2018– Gibson Oncology, LLC (“Gibson”), a privately held clinical stage company developing a novel class of oncology drugs for treating adult and pediatric cancers resistant to traditional cancer drugs, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to LMP-400, Gibson’s novel small molecule
Read more Read more
SLFN11 as predictor of Indenos in cancer treatment Read more
Randall Riggs selected as President and CEO of Gibson Oncology, LLC. Read more
Gibson Oncology LLC acquires assets of Linus Oncology, Inc Read more
Gibson Oncology Adds Two Prominent Experts Read more
The National Cancer Institute (NCI) Demonstrates Anti-Cancer Efficacy and Safety Read more
Gibson Oncology,LLC is composed of proven academic researchers and bio tech entrepreneurs who are excited to be developing effective and safer novel oncology drugs to treat resistant cancers with a focus on children.